Helius Medical Technologies (NASDAQ: HSDT) is one of 59 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Helius Medical Technologies to similar businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.
This table compares Helius Medical Technologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Helius Medical Technologies||-2,965.26%||-289.95%||-188.52%|
|Helius Medical Technologies Competitors||-310.31%||-90.21%||-20.70%|
This table compares Helius Medical Technologies and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Helius Medical Technologies||$1.50 million||-$9.78 million||-1.19|
|Helius Medical Technologies Competitors||$1.01 billion||$119.86 million||23.14|
Helius Medical Technologies’ rivals have higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
8.0% of Helius Medical Technologies shares are held by institutional investors. Comparatively, 45.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 17.4% of Helius Medical Technologies shares are held by company insiders. Comparatively, 16.4% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings for Helius Medical Technologies and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Helius Medical Technologies||0||0||0||0||N/A|
|Helius Medical Technologies Competitors||339||1008||1699||86||2.49|
As a group, “Electromedical equipment” companies have a potential upside of 7.10%. Given Helius Medical Technologies’ rivals higher probable upside, analysts plainly believe Helius Medical Technologies has less favorable growth aspects than its rivals.
Risk & Volatility
Helius Medical Technologies has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Helius Medical Technologies’ rivals have a beta of 24.48, indicating that their average stock price is 2,348% more volatile than the S&P 500.
Helius Medical Technologies rivals beat Helius Medical Technologies on 9 of the 10 factors compared.
About Helius Medical Technologies
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator (PoNS), a medical device in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function. The company is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.